Stock listing

NASDAQ:SANA Sana Biotechnology, Inc. Stock

Home listing (NASDAQ) of Sana Biotechnology, Inc.

Follow Sana Biotechnology, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SANA

$1.59 USD -0.26 (-14.1%)

Close on Nov 20, 2026

Past year -50.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.57 – $1.75 USDNov 20, 2026
Volume
4.45M sharesNov 20, 2026
Market cap
$476.4M USDAt the close on Nov 20, 2026 · price × 299.6M shares outstanding
52-week range
$1.57 – $5.49 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$9.33M USDMedian day 2.92M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sana Biotechnology, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SANA · Home$1.59 USD-0.26 (-14.1%)4,452,514$1.70$1.75$1.565$1.85Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SANA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.59-0.26-14.1%$1.70$1.75$1.5654,452,514
$1.85-0.03-1.6%$1.86$1.995$1.8412,659,158
$1.880.000.0%$1.88$1.92$1.842,632,278
$1.88-0.14-6.9%$1.99$2.019$1.874,343,900
$2.02+0.01+0.5%$2.05$2.05$1.863,195,306
$2.01-0.28-12.2%$2.25$2.25$2.003,665,134
$2.29-0.14-5.8%$2.43$2.449$2.282,710,924
$2.43-0.035-1.4%$2.42$2.52$2.3152,533,522
$2.465+0.095+4.0%$2.45$2.48$2.283,259,857
$2.37+0.03+1.3%$2.49$2.49$2.2832,288,241
$2.34-0.22-8.6%$2.53$2.53$2.283,066,256
$2.56+0.12+4.9%$2.55$2.62$2.4552,627,698
$2.44+0.04+1.7%$2.43$2.52$2.401,818,638
$2.40-0.17-6.6%$2.57$2.585$2.372,594,455
$2.57-0.15-5.5%$2.68$2.72$2.512,075,932
$2.72+0.09+3.4%$2.65$2.768$2.653,307,850
$2.63+0.16+6.5%$2.43$2.64$2.383,273,499
$2.47+0.11+4.7%$2.37$2.48$2.332,619,899
$2.36+0.03+1.3%$2.33$2.385$2.291,509,332
$2.33-0.04-1.7%$2.35$2.38$2.2451,707,921
$2.37+0.02+0.9%$2.31$2.44$2.282,427,176
$2.35-0.01-0.4%$2.38$2.39$2.3152,395,417
$2.36+0.06+2.6%$2.27$2.42$2.253,487,153
$2.30+0.03+1.3%$2.32$2.359$2.2252,606,588
$2.27-0.205-8.3%$2.46$2.51$2.253,088,800
$2.475+0.145+6.2%$2.36$2.51$2.352,916,200
$2.33-0.08-3.3%$2.37$2.43$2.322,762,300
$2.41-0.21-8.0%$2.60$2.635$2.374,903,600
$2.62-0.17-6.1%$2.77$2.77$2.592,669,300
$2.790.000.0%$2.79$2.87$2.772,918,200
$2.79+0.07+2.6%$2.72$2.81$2.664,514,100
$2.72-0.03-1.1%$2.71$2.845$2.704,314,700
$2.75-0.13-4.5%$2.94$2.975$2.743,759,400
$2.88-0.01-0.3%$2.90$2.93$2.825,391,800
$2.890.000.0%$2.95$3.00$2.8553,495,300
$2.89-0.025-0.9%$2.89$3.05$2.853,762,200
$2.915+0.005+0.2%$2.97$3.045$2.8553,245,600
$2.91-0.02-0.7%$2.945$3.055$2.893,042,800
$2.93-0.015-0.5%$2.92$2.98$2.862,264,400
$2.945-0.015-0.5%$2.96$3.00$2.902,880,200
$2.96-0.12-3.9%$3.04$3.047$2.883,505,800
$3.08-0.25-7.5%$3.33$3.33$3.0143,835,400
$3.33+0.23+7.4%$3.15$3.36$3.107,167,600
$3.100.000.0%$3.14$3.16$3.042,004,400
$3.100.000.0%$3.09$3.11$3.027,408,800
$3.10+0.18+6.2%$3.08$3.275$3.0552,916,000
$2.92-0.24-7.6%$3.17$3.21$2.8659,724,400
$3.16-0.04-1.3%$3.20$3.20$3.0752,468,400
$3.20+0.07+2.2%$3.135$3.25$3.102,378,800
$3.13+0.04+1.3%$3.13$3.165$3.013,278,900
$3.09-0.08-2.5%$3.10$3.19$3.004,616,100
$3.17-0.28-8.1%$3.51$3.525$3.168,650,600
$3.45-0.40-10.4%$3.78$3.83$3.3954,986,000
$3.85-0.07-1.8%$3.86$3.915$3.811,239,200
$3.92+0.03+0.8%$3.93$3.96$3.802,637,200
$3.89+0.06+1.6%$3.82$4.08$3.7952,140,800
$3.83-0.04-1.0%$3.82$3.915$3.721,696,600
$3.87-0.06-1.5%$3.87$3.90$3.762,226,300
$3.93-0.16-3.9%$4.05$4.115$3.892,143,500
$4.09-0.07-1.7%$4.16$4.215$4.071,719,200
$4.16+0.06+1.5%$4.07$4.19$4.042,292,600
$4.10+0.32+8.5%$3.88$4.15$3.853,001,200
$3.78-0.13-3.3%$3.89$3.89$3.711,924,700
$3.91+0.17+4.5%$3.78$4.095$3.742,923,100
$3.74-0.36-8.8%$4.06$4.08$3.732,745,700
Ticker
NASDAQ:SANA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Sana Biotechnology, Inc. news

Sana Biotechnology, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 123 in all · newest Nov 5, 2026 · oldest 2021
Decks
12 decks · latest September 2026

Where Sana Biotechnology, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SANA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SANABOATSUnited StatesUSD

Valuation

Price/book 2.6× against a median of 2.3×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$408.5M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.3×
Beta vs S&P 500
2.29

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Sana Biotechnology, Inc. · NASDAQ:SANAUS$476.4MUS$408.5Mn/an/an/a2.6×n/a0.3×2.29
Steminent Biotherapeutics, Inc. · TPEX:7729US$497.0MUS$470.5Mn/an/an/a16.2×n/a0.0×n/a
Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575US$495.2MUS$407.3Mn/a23.3×n/a2.2×−200.8%0.0×n/a
TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872US$489.2MUS$391.8Mn/an/an/a5.0×n/a0.1×n/a
Crescent Biopharma, Inc. · NASDAQ:CBIOUS$482.9MUS$196.0Mn/a13.1×n/a1.8×−727.6%0.0×0.92
Regenxbio Inc. · NASDAQ:RGNXUS$473.4MUS$289.0Mn/a1.9×n/a3.2×−113.9%0.5×1.60
Monopar Therapeutics Inc. · NASDAQ:MNPRUS$467.6MUS$362.8Mn/an/an/a3.7×n/a0.0×1.18
BlossomHill Therapeutics, Inc. · NASDAQ:BLSMUS$461.2MUS$259.4Mn/an/an/a2.2×n/a0.1×n/a
Neurogene Inc. · NASDAQ:NGNEUS$458.5MUS$106.4Mn/an/an/a1.3×n/a0.0×1.47
Assembly Biosciences, Inc. · NASDAQ:ASMBUS$454.4MUS$142.3Mn/a2.1×n/a1.5×−16.6%0.0×1.00
Shattuck Labs, Inc. · NASDAQ:STTKUS$454.2MUS$260.4Mn/an/an/a2.4×n/a0.0×1.10
Median of the othersUS$470.5MUS$274.7M7.6×2.3×−157.3%0.0×1.14

Forecasts

6 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
8.57 USD · Analysts' mean
EPS, year to Dec 2026
-0.49 · 4 analysts

Team and board

Officers

OfficerRole
Steve HarrPresident and Chief Executive Officer
Brian PiperExecutive Vice President, Chief Financial Officer
Aaron GrossmanExecutive Vice President, Chief Legal Officer
Dhavalkumar PatelExecutive Vice President, Chief Scientific Officer
Gary MeiningerExecutive Vice President, Chief Medical Officer
Snehal PatelExecutive Vice President, Chief Technical Officer

Board

DirectorRole
Hans BishopChairman
Alise ReicinDirector
Josh BilenkerDirector
Michelle SeitzDirector
Patrick YangDirector
Richard MulliganVice Chairman
Rob RosielloDirector
Robert NelsenDirector
Steve HarrPresident and Chief Executive Officer

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+1.3%
Q2 2026Aug 10, 2026 · After close+5.0%
Q1 2026May 11, 2026 · After close−8.4%
Q4 2025Mar 24, 2026−0.6%
Q3 2025Nov 6, 2025 · After close+1.0%
Q2 2025Aug 11, 2025 · After close+6.5%
Q1 2025May 8, 2025 · After close+0.6%
Q4 2024Feb 26, 2025 · Before open+0.6%
Q3 2024Nov 8, 2024 · Before open−3.1%
Q2 2024Aug 8, 2024 · After close+5.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close−21.0%
Q4 2023Feb 29, 2024 · After close+12.3%
Q3 2023Nov 8, 2023 · After close−1.1%
Q2 2023Aug 3, 2023 · After close−0.9%
Q1 2023May 8, 2023 · After close+10.3%
Q4 2022Mar 16, 2023 · After close+7.4%
Q3 2022Nov 2, 2022 · After close−13.9%
Q2 2022Aug 4, 2022 · After close+11.1%
Q1 2022May 10, 2022 · After close−13.5%
Q4 2021Mar 16, 2022 · Before open+11.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck29 slidesSeptember 2026
Investor Presentation (January 2026)Investor deck29 slidesJan 14, 2026
Investor Presentation (January 2025)Investor deck35 slidesJan 13, 2025
Investor Presentation (January 2024)Investor deck36 slidesJan 9, 2024
Investor Presentation (December 2023)Investor deck28 slidesDec 11, 2023
Investor Presentation (October 2023)Investor deck28 slidesOct 10, 2023
Investor Presentation (September 2023)Investor deck47 slidesSep 13, 2023
Investor Presentation (June 2023)Investor deck25 slidesJun 7, 2023
Investor Presentation (January 2023)Investor deck32 slidesJan 10, 2023
Investor Presentation (June 2022)Investor deck30 slidesJun 14, 2022
All 12 decks
DeckKindSlidesDate
Investor Presentation (January 2022)Investor deck28 slidesJan 11, 2022
Investor Presentation (September 2021)Investor deck32 slidesSep 13, 2021

Open Decks

Financings

RaiseDate
Strategic investment of equity
Announced: strategic investment
Buyers: Mayo Clinic
Apr 13, 2026
At-the-market programme of common stock
Tranche closed: US$47.4M raised
Mar 3, 2026
Public offering of common stock
Closed: US$86.3M raised · US$3.35 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), Goldman Sachs & Co. LLC (co-lead), BofA Securities (co-lead), TD Cowen (co-lead)
Aug 20, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$25.00 a share on Feb 3, 2021.

Price
US$25.00 a share
Shares offered
23,500,000 shares of common stock
Offering size
US$587.5 million
Underwriters' option
Up to 3,525,000 more shares
Underwriters
Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, BofA Securities · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceNov 10, 2020
Filed publiclyJan 13, 2021
Amended 3 timesNewest Feb 3, 2021
Shares registered with an exchangeJan 25, 2021
Declared effective by the SECFeb 3, 2021
Final prospectus, with the priceFeb 5, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Feb 5, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue0000000
Cost of revenue12.8M15.5M30.9M27.7M17.9M10.2M3.92M1.00K
Gross profit-12.8M-15.5M-30.9M-27.7M-17.9M-10.2M-3.92M-1.00K
Research and development132.0M215.7M261.8M285.9M248.6M132.9M99.6M4.01M
Selling, general and administrative44.3M64.0M73.3M71.6M50.4M28.3M21.8M8.41M
Operating income-250.3M-272.7M-293.1M-272.6M-356.9M-286.1M-141.2M-8.22M
Depreciation and amortization12.8M15.5M17.5M15.6M11.1M5.92M1.83M1.00K
EBITDA-237.5M-257.2M-275.6M-257.0M-345.8M-280.2M-139.3M-8.22M
Interest expense15.6M11.1M02.83M0
Income before tax-244.2M-266.8M-283.3M-269.5M-355.9M-285.3M-138.3M-13.2M
Income tax0-3.09M-11.7M-6.67M-7.55M
Net income-244.2M-266.8M-283.3M-269.5M-355.9M-285.3M-130.8M-13.2M
Earnings per share, basic-0.96-1.16-1.46-1.43-2.14-21.92-26.68-0.07
Earnings per share, diluted-0.96-1.16-1.46-1.43-2.14-21.92-26.68

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents71.9M127.6M133.5M176.8M253.0M124.8M81.8M30.6M
Short-term investments66.5M24.9M71.7M247.2M298.0M253.5M59.0M0
Current assets148.7M160.8M213.5M444.4M558.1M384.5M144.3M32.6M
Property, plant and equipment26.9M77.3M70.7M66.9M65.5M46.8M68.8M585.0K
Goodwill140.6M140.6M140.6M140.6M140.6M140.6M140.6M0
Total assets416.9M501.0M565.3M822.7M1.13B730.3M415.2M34.3M
Accounts payable1.67M5.21M4.11M2.86M2.22M2.25M0289.0K
Current liabilities78.7M45.4M64.5M111.5M99.2M31.5M19.3M1.78M
Total debt78.9M94.2M104.1M108.3M110.9M71.9M47.7M
Total liabilities256.0M250.5M277.8M323.4M400.9M298.6M557.7M47.5M
Shareholders' equity160.9M250.5M287.5M499.3M728.5M-421.2M-142.5M-13.2M
Shares outstanding266.7M223.9M197.9M191.0M184.9M16.2M191.4M187.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-143.8M-223.2M-253.6M-290.1M-251.1M-138.0M-85.5M-13.5M
Capital spending-938.0K-33.4M-20.0M-20.9M-29.9M-23.9M-26.1M-460.0K
Free cash flow-144.8M-256.6M-273.6M-310.9M-280.9M-161.9M-111.6M-14.0M
Cash from investing-40.2M17.5M172.0M210.6M-245.8M-252.6M-87.9M-780.0K
Cash from financing128.7M199.7M31.6M4.91M631.8M435.7M223.7M45.7M
Share buybacks601.0K626.4M
Change in cash-55.3M-5.95M-49.9M-74.6M134.9M45.1M50.4M31.4M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
8-K · Current reportSep 8, 2026Current reportSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
8-K · Current reportJun 5, 2026Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeMay 21, 2026Big-stake noticeSEC
8-K · Current reportMay 15, 2026Current reportSEC
S-8 · Registration statement for employee plansMay 11, 2026Offer documentSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
8-K · Current reportApr 24, 2026Management or board changeSEC
424B5 · ProspectusApr 13, 2026Offer documentSEC
8-K · Current reportApr 13, 2026Current reportSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
S-3ASR · Registration statementMar 3, 2026Offer documentSEC
10-K · Annual reportMar 3, 2026Annual reportSEC
8-K · Current reportMar 3, 2026ResultsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 18, 2026Insider tradeSEC
8-K · Current reportFeb 17, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
8-K · Current reportJan 14, 2026Current reportSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
UPLOAD · Letter from the SECSep 10, 2025Other filingsSEC
8-K · Current reportSep 5, 2025Management or board changeSEC
8-K · Current reportAug 29, 2025Management or board changeSEC
CORRESP · Letter to the SECAug 13, 2025Other filingsSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
8-K · Current reportAug 7, 2025Material contractSEC
424B5 · ProspectusAug 7, 2025Offer documentSEC
424B5 · ProspectusAug 6, 2025Offer documentSEC
8-K · Current reportAug 6, 2025ResultsSEC
UPLOAD · Letter from the SECJul 30, 2025Other filingsSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
8-K · Current reportJun 23, 2025Current reportSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
424B5 · ProspectusMay 8, 2025Offer documentSEC
S-8 · Registration statement for employee plansMay 8, 2025Offer documentSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 25, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveMar 24, 2025Other filingsSEC
POS AM · Amendment to an effective registrationMar 17, 2025Offer documentSEC
10-K · Annual reportMar 17, 2025Annual reportSEC
8-K · Current reportMar 17, 2025ResultsSEC
POSASRMar 14, 2025Other filingsSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 31, 2025Big-stake noticeSEC
144 · Notice of proposed saleJan 16, 2025Other filingsSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleNov 26, 2024Other filingsSEC
144 · Notice of proposed saleNov 25, 2024Other filingsSEC
3/A · Initial statement of ownership, amendedNov 21, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 8, 2024Quarterly reportSEC
8-K · Current reportNov 8, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
144 · Notice of proposed saleOct 21, 2024Other filingsSEC
3 · Initial statement of ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 9, 2024Insider tradeSEC
8-K · Current reportOct 8, 2024Management or board changeSEC
4 · Change in ownershipSep 26, 2024Insider tradeSEC
144 · Notice of proposed saleSep 25, 2024Other filingsSEC
144 · Notice of proposed saleSep 24, 2024Other filingsSEC
8-K · Current reportSep 12, 2024Management or board changeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4/A · Change in ownership, amendedJul 15, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 15, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 15, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 15, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 15, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 15, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 15, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 15, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 15, 2024Insider tradeSEC
4 · Change in ownershipJul 8, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 7, 2024Meeting outcomeSEC
S-8 · Registration statement for employee plansMay 8, 2024Offer documentSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
8-K · Current reportApr 18, 2024Management or board changeSEC
4 · Change in ownershipApr 8, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 8, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedApr 3, 2024Big-stake noticeSEC
4 · Change in ownershipMar 11, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedMar 7, 2024Big-stake noticeSEC
S-3ASR · Registration statementMar 1, 2024Offer documentSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC
8-K · Current reportFeb 29, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
4 · Change in ownershipFeb 12, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
8-K · Current reportFeb 8, 2024Material contractSEC
424B5 · ProspectusFeb 8, 2024Offer documentSEC
FWP · Free writing prospectusFeb 7, 2024Offer documentSEC
424B5 · ProspectusFeb 7, 2024Offer documentSEC
8-K · Current reportFeb 7, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedJan 26, 2024Big-stake noticeSEC
8-K · Current reportJan 9, 2024Current reportSEC
4 · Change in ownershipJan 8, 2024Insider tradeSEC
4 · Change in ownershipJan 8, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
144 · Notice of proposed saleDec 15, 2023Other filingsSEC
8-K · Current reportDec 11, 2023Current reportSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportNov 8, 2023ResultsSEC
4 · Change in ownershipNov 3, 2023Insider tradeSEC
4 · Change in ownershipNov 3, 2023Insider tradeSEC
4 · Change in ownershipNov 3, 2023Insider tradeSEC
8-K · Current reportOct 10, 2023Current reportSEC
4 · Change in ownershipOct 6, 2023Insider tradeSEC
4 · Change in ownershipOct 6, 2023Insider tradeSEC
4 · Change in ownershipSep 15, 2023Insider tradeSEC
8-K · Current reportSep 13, 2023Current reportSEC
8-K · Current reportAug 21, 2023Current reportSEC
10-Q · Quarterly reportAug 3, 2023Quarterly reportSEC
8-K · Current reportAug 3, 2023ResultsSEC
4 · Change in ownershipJul 6, 2023Insider tradeSEC
4 · Change in ownershipJul 6, 2023Insider tradeSEC

This page holds 200 of 392 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Sana Biotechnology, Inc.’s releases · as of Oct 29, 2026

Common shares
299,634,951
Fully diluted
299,634,951

Fully diluted

LineSharesAs of
Common shares299,634,951Oct 29, 2026

Share count over time

CountShares
Oct 29, 2026299,634,951

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
ARCH Venture Management, LLC45.9M15.3%US$134MSep 30, 2026
Fidelity37.3M12.4%US$109MSep 30, 2026
Flagship Pioneering, LLC25M8.3%US$72.9MSep 30, 2026
Ra Capital Management, L.P.18.8M6.3%US$54.7MSep 30, 2026
BlackRock16.4M5.5%US$47.8MSep 30, 2026
Vanguard12.1M4.0%US$35.2MSep 30, 2026
CPP Investments10.2M3.4%US$29.8MSep 30, 2026
State Street9.58M3.2%US$27.9MSep 30, 2026
Geode Capital4.65M1.6%US$13.6MSep 30, 2026
Bank of America4.63M1.5%US$13.5MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Marex Group Ltd3.99M1.3%US$11.6MSep 30, 2026
Morgan Stanley3.02M1.0%US$8.81MSep 30, 2026
Alphabet Inc.2.81M0.94%US$8.21MSep 30, 2026
Goldman Sachs2.68M0.89%US$7.81MSep 30, 2026
Marshall Wace, LLP2.26M0.75%US$6.6MSep 30, 2026
Integral Health Asset Management, LLC2M0.67%US$5.83MSep 30, 2026
TD1.99M0.66%US$5.8MSep 30, 2026
Schwab1.7M0.57%US$4.95MSep 30, 2026
Northern Trust1.48M0.50%US$4.32MSep 30, 2026
Renaissance Technologies1.42M0.47%US$4.14MSep 30, 2026
UBS1.35M0.45%US$3.95MSep 30, 2026
Woodline Partners LP1.32M0.44%US$3.84MSep 30, 2026
Citadel1.2M0.40%US$3.49MSep 30, 2026
Jacobs Levy Equity Management, Inc904K0.30%US$2.63MSep 30, 2026
Omega Fund Management, LLC844K0.28%US$2.46MSep 30, 2026
JPMorgan780K0.26%US$2.27MSep 30, 2026
Crestline Management, L.P.756K0.25%US$2.2MSep 30, 2026
Moore Capital Management, LP746K0.25%US$2.17MSep 30, 2026
ArrowMark Colorado Holdings LLC685K0.23%US$2MSep 30, 2026
Hrt Financial LP684K0.23%US$1.99MSep 30, 2026
DWS619K0.21%US$1.81MSep 30, 2026
AQR Capital Management LLC506K0.17%US$1.48MSep 30, 2026
Invesco497K0.17%US$1.45MSep 30, 2026
Susquehanna466K0.16%US$1.36MSep 30, 2026
BNY435K0.15%US$1.27MSep 30, 2026
Millennium390K0.13%US$1.14MSep 30, 2026
Nuveen353K0.12%US$1.03MSep 30, 2026
Swiss National Bank348K0.12%US$1.01MSep 30, 2026
Two Sigma322K0.11%US$939KSep 30, 2026
Baker Bros. Advisors LP310K0.10%US$905KSep 30, 2026
Quadrature Capital Ltd304K0.10%US$885KSep 30, 2026
Dimensional286K0.10%US$833KSep 30, 2026
T. Rowe Price274K0.09%US$799KSep 30, 2026
AllianceBernstein271K0.09%US$789KSep 30, 2026
Franklin Templeton261K0.09%US$669KSep 30, 2026
Point72 Asset Management, L.P.253K0.08%US$737KSep 30, 2026
Arrowstreet Capital, Limited Partnership247K0.08%US$719KSep 30, 2026
Rafferty Asset Management, LLC237K0.08%US$691KSep 30, 2026
Squarepoint Ops LLC236K0.08%US$688KSep 30, 2026
Rhumbline Advisers215K0.07%US$626KSep 30, 2026

This page holds 50 of 193 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Growth Company Fund10.5M3.5%US$34.7MMay 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF7.08M2.4%US$24.7MJun 30, 2026
Vanguard Total Stock Market Index Fund6.25M2.1%US$21.8MJun 30, 2026
iShares Russell 2000 ETF4.81M1.6%US$16.8MJun 30, 2026
Fidelity Growth Company K6 Fund3.11M1.0%US$10.3MMay 31, 2026
Fidelity Series Growth Company Fund2.86M0.95%US$9.43MMay 31, 2026
Fidelity Small Cap Index Fund2.01M0.67%US$6.29MJul 31, 2026
Vanguard Extended Market Index Fund1.92M0.64%US$6.7MJun 30, 2026
iShares Russell 2000 Growth ETF1.68M0.56%US$5.87MJun 30, 2026
iShares Biotechnology ETF1.28M0.43%US$4.46MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Select Biotechnology Portfolio1.26M0.42%US$4.17MMay 31, 2026
Vanguard Russell 2000 Index Fund864K0.29%US$2.85MMay 31, 2026
Fidelity Extended Market Index Fund844K0.28%US$2.78MMay 31, 2026
Schwab U.S. Small-Cap ETF771K0.26%US$2.54MMay 31, 2026
Vanguard Health Care Index Fund520K0.17%US$1.72MMay 31, 2026
Schwab Small-Cap Index Fund447K0.15%US$1.4MJul 31, 2026
iShares U.S. Small-Cap Equity Factor ETF422K0.14%US$1.32MJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF387K0.13%US$1.21MJul 31, 2026
Master Small Cap Index Series343K0.11%US$1.2MJun 30, 2026
Fidelity Total Market Index Fund296K0.10%US$978KMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF254K0.08%US$887KJun 30, 2026
Fidelity Series Total Market Index Fund247K0.08%US$816KMay 31, 2026
Nuveen Small Cap Blend Index Fund244K0.08%US$762KJul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares240K0.08%US$753KJul 31, 2026
Goldman Sachs Small Cap Equity Insights Fund223K0.07%US$699KJul 31, 2026
BlackRock Advantage Small Cap Core Fund206K0.07%US$680KMay 29, 2026
EQ/2000 Managed Volatility Portfolio200K0.07%US$700KJun 30, 2026
Fidelity Small Cap Growth Index Fund172K0.06%US$601KJun 30, 2026
Fidelity Nasdaq Composite Index Fund166K0.06%US$548KMay 31, 2026
PACE Small/Medium Co Growth Equity Investments153K0.05%US$479KJul 31, 2026
Optimize Strategy Index ETF140K0.05%US$489KJun 30, 2026
LVIP State Street Small-Cap Index Fund132K0.04%US$460KJun 30, 2026
Schwab U.S. Broad Market ETF126K0.04%US$415KMay 31, 2026
Vanguard Russell 2000 Value Index Fund120K0.04%US$395KMay 31, 2026
Virtus Biotech Clinical Trials Etf116K0.04%US$363KJul 31, 2026
Dimensional U.S. Small Cap ETF111K0.04%US$347KJul 31, 2026
Nuveen Equity Index Fund104K0.03%US$326KJul 31, 2026
EQ/Small Company Index Portfolio101K0.03%US$351KJun 30, 2026
U.S. Small Cap Portfolio98,9900.03%US$310KJul 31, 2026
Small Cap Index Fund94,9750.03%US$331KJun 30, 2026
Vanguard Balanced Index Fund94,4540.03%US$330KJun 30, 2026
Small Company Growth Portfolio93,4370.03%US$326KJun 30, 2026
Fidelity Nasdaq Composite Index ETF92,6820.03%US$306KMay 31, 2026
Fidelity ZERO Total Market Index Fund91,0870.03%US$285KJul 31, 2026
NVIT Multi-Manager Small Company Fund89,4000.03%US$312KJun 30, 2026
Global X Russell 2000 ETF87,7200.03%US$275KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund87,4440.03%US$305KJun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund84,8630.03%US$266KJul 31, 2026
NVIT Small Cap Value Fund80,8000.03%US$282KJun 30, 2026
Fidelity MSCI Health Care Index ETF80,3300.03%US$251KJul 31, 2026

This page holds 50 of 145 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Robert Nelsen15.40%46.2MJun 30, 2026Schedule 13G
FMR LLC12.50%37.3MSep 30, 2026Schedule 13G
Ra Capital Management, L.P.6.30%18.8MMay 14, 2026Schedule 13G
BlackRock, Inc.5.10%13.6MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Mary Agnes Wilderotter
Other companies: Okta, Inc. (Director · Since at least Aug 13, 2025); Fortinet, Inc. (Director · Since at least Apr 19, 2024); Costco Wholesale Corporation (Director · Since at least Jun 7, 2022); DocuSign, Inc. (Director · Since at least May 28, 2022); Lyft, Inc. (Director · May 27, 2022 – Aug 28, 2023 · Past); Hewlett Packard Enterprise Company (Director · Apr 5, 2022 – Apr 5, 2022 · Past)
Director · Since at least Jun 6, 2022
Sunil Agarwal
Other companies: Astria Therapeutics Inc (Director · Since at least Apr 5, 2024); Arvinas, Inc. (Director · Since at least Jun 15, 2023); Juno Therapeutics Inc (President of R & D · Apr 13, 2017 – Mar 5, 2018 · Past); MyoKardia Inc (Director · Mar 4, 2016 – Nov 17, 2020 · Past); Calithera Biosciences, Inc. (Director · Sep 29, 2015 – Jun 1, 2022 · Past); Ultragenyx Pharmaceutical Inc. (Chief Medical Officer · Aug 19, 2015 – Aug 19, 2016 · Past)
EVP, Head of Development & CMO · Feb 3, 2021 – Mar 3, 2022 · Past
Alise Reicin
Other companies: Immatics N.V. (Director · Since at least Mar 18, 2026); Tectonic Therapeutic, Inc. (President and CEO, Director · Since at least Jun 20, 2024); Q32 Bio Inc. (Director · Jul 11, 2019 – Jun 14, 2023 · Past); Celgene Corporation (PRES., GLOBAL CLINICAL DEV. · Nov 1, 2018 – Nov 20, 2019 · Past)
Director · Since at least Feb 3, 2021
Hans Bishop
Other companies: Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Celgene Corporation (Director · Apr 18, 2018 – Nov 20, 2019 · Past); Agilent Technologies, Inc. (Director · Jul 18, 2017 – Mar 15, 2024 · Past); Juno Therapeutics Inc (CEO & President, Director · Jun 9, 2016 – Mar 5, 2018 · Past)
Chairman · Since at least Feb 3, 2021
Richard Mulligan
Other companies: International Flavors & Fragrances, Inc. (Director · Since at least Oct 20, 2025); Bausch Health Companies Inc. (Director · May 17, 2024 – May 16, 2025 · Past)
Vice Chairman · Since at least Jun 6, 2024
Robert L Rosiello
Other companies: Seres Therapeutics, Inc. (Director · Since at least Aug 5, 2025); Omega Therapeutics Inc (Director · Oct 2, 2024 – Oct 2, 2024 · Past)
Director · Since at least Jun 5, 2025
Geoffrey von Maltzahn
Other companies: Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Jun 30, 2021 · Past)
Director · Feb 3, 2021 – Feb 8, 2021 · Past
Aaron GrossmanExecutive Vice President, Chief Legal Officer · Since at least Nov 4, 2026
Bernard J CassidyEVP & General Counsel · Mar 7, 2024 – Mar 6, 2025 · Past
Brian PiperExecutive Vice President, Chief Financial Officer · Since at least Feb 17, 2026
All 23 people
PersonSeat
Dhavalkumar PatelExecutive Vice President, Chief Scientific Officer · Since at least Mar 24, 2026
Gary MeiningerExecutive Vice President, Chief Medical Officer · Since at least Jul 13, 2026
Jim MacDonaldChief Executive Officer and member of its Board of Directors · Sep 16, 2025 – Nov 4, 2026 · Past
Josh BilenkerDirector · Since at least Nov 4, 2026
Joshua H BilenkerDirector · Since at least Jun 6, 2024
Michelle SeitzDirector · Since at least Nov 5, 2026
Patrick YangDirector · Since at least Nov 5, 2026
Robert NelsenDirector · Since at least Nov 5, 2026
Rob RosielloDirector · Since at least Nov 4, 2026
Snehal PatelExecutive Vice President, Chief Technical Officer · Since at least Nov 4, 2026
Steve HarrPresident & CEO, Director · Since at least Mar 5, 2026
Steve HarrPresident and Chief Executive Officer · Since at least Aug 10, 2026
Susan D WyrickSee Remarks · Since at least Oct 4, 2024

Open People

Log in to ask 6ix AI your own questions about Sana Biotechnology, Inc.